In this study, the efficacy of bicalutamide addition, a second-generation AR antagonist that is widely used in prostate cancer, to conventional chemotherapy (doxorubicin and docetaxel) used in breast cancer has been evaluated for IMC and IBC [15,19,39,40]. The gene discussed is AR; the disease is prostate carcinoma.